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Previewssmall differences observed were suffi-
cient to influence Th cell differentiation
via altered mTORC1-mTORC2 and Akt-
PKC-q activation. Moreover, the strength
of the CD3 and CD28 signal might be
important for selective mTOR pathway
activation or other environmental factors
influence the Th cell differentiation
process via mTOR signaling. Finally, as
nutrients such as amino acids or glucose
directly control the activation of the
mTOR pathway, it is tempting to hypothe-
size that nutrients do not merely control
T cell proliferation but that the nutritional
status might also control Th cell differenti-
ation via the mTOR signaling complex.REFERENCES
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Whether apoptosis is relevant for interclonal competition of T cells after antigen encounter has remained
uncertain. In this issue of Immunity, Wensveen et al. (2010) establish a critical role for the proapoptotic
BH3-only protein Noxa in this selection process.Apoptosis plays a critical role in the selec-
tion of functionally competent immune
cells. During lymphocyte development,
apoptosis eliminates cells that lack antigen
receptor expression in a process known as
‘‘death by neglect,’’ but also mediates the
death of cells that express potentially
autoreactive antigen receptors during
‘‘negative selection,’’ critical for generating
tolerance. Both types of cell death are
controlled by B cell lymphoma-2 (Bcl-2)
family proteins that fall into pro- and antia-
poptotic groups and that integrate different
forms of cell stress as well as develop-
mental cues at the level of mitochondria in
order to preserve cell survival or initiate
cell death (Strasser, 2005). Apoptosis has
also been recognized as critical for affinity
maturationofBcellscompeting fora limited
amount of antigen and supporting cyto-
kines in germinal center reactions. This
process secures that only clones ex-
pressing B cell receptors with the highest
affinity are able to thrive. Bcl2l11, alsoknown as Bcl-2 interacting mediator of
cell death (Bim), a BH3-only protein
belonging to one proapoptotic subclass
of the Bcl-2 family with at least eight
members, has been shown to be critical
for this selection process (Fischer et al.,
2007). Bim is also critical for T cell deletion
after antigen clearance inwhich otherBH3-
only proteins, such as Puma or Noxa (also
known as Pmaip1), can play auxiliary roles
(Bauer et al., 2006). Notably, the latter two
proteins have been identified as direct
target genes of the tumor suppressor p53,
activated in order to execute apoptosis
induced by DNA damage. However, the
physiological role of Noxa has remained
rather obscure, given that its loss confers
only mild resistance to DNA-damage-
induced apoptosis, and only in selected
cell types (Ploner et al., 2008).
One of the first hints that Noxa can
act outside the DNA-damage response
came from the demonstration that its
expression was induced in response toTCR ligation in human naive T cells and
that repression of protein expression by
RNA interference provided a selective
advantage in cell-growth competition
experiments to Jurkat T acute lympho-
blastic leukemia and primary activated
T cells under conditions of glucose limita-
tion (Alves et al., 2006). Others observed
that Noxa limits the lifespan of memory
T cells (Yamashita et al., 2008) or, together
with Bim, restricts survival of NK cells
in the absence of their major survival
cytokine, IL-15 (Huntington et al., 2007).
Performing a consequent follow up of
their initial observations, Wensveen et al.
(2010) now provide compelling evidence
thatNoxa limits the survival of T cell clones
that express low-affinity TCRs during
interclonal competition, a process that
leads to the outgrowth of the ‘‘best-fit’’
high-avidityTcell clones froma largepanel
of antigen-reactive naive T cells during
antigenic challenge (Malherbe et al., 2004;

































Figure 1. Noxa Sets the Threshold for T Cell Apoptosis during Interclonal Competition
High-affinity TCR ligation induces transcription of genes relevant for cell growth and survival (e.g., Il2, Bcl2l1, and Bcl2a1a). Secreted IL-2 drives autocrine induc-
tion of its receptor components. Noxa expression rises gradually over time leading to Mcl-1 codegradation that is compensated by IL-2 receptor-mediated
increases of Mcl-1 protein, sufficiently high to also neutralize proapoptotic Bim. In response to low-affinity TCR ligation, IL-2 and subsequent CD25 production
are insufficient to maintain high-enough Mcl-1 levels that drop below threshold leading to a relative increase in free Bim that triggers apoptosis.
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PreviewsExpression analysis of 40 preselected
genes involved in cell death signaling
revealed that Noxa mRNA gradually
increases upon TCR ligation in mouse
CD8+ T cells. This increasewas separated
well in time from the rapid increase of
mRNAs encoding the prosurvival Bcl-2
family proteins Bcl-xL and Bfl1/A1 and
was paralleled by a posttranslational
increase in proapoptotic Bim and antia-
poptotic Mcl-1. Notably, after Noxa accu-
mulation reached a plateau, amounts of
Mcl-1, its preferred binding partner within
the Bcl-2 family and most critical for
peripheral T and B cell survival, declined
(Strasser, 2005). This observation is
consistent with the fact that Noxa-Mcl-1
interaction initiates their proteasomal co-
degradation (Ploner et al., 2008). Keeping
in mind that Mcl-1 reportedly neutralizes
Bim by direct binding in unstressed cells,
they investigated possible quantitative
differences in Mcl-1-Bim complexes in
wild-type and Pmaip1/ T cells after TCR
ligation. Consistent with one model of
BH3-only protein action, Bim was found
in complex with Mcl-1 for an extended
period of time in the absence of Noxa,
suggesting that Bim may become acti-
vated less efficiently.
A long-term follow up of Pmaip1/
mice revealed accumulation of CD8+
CD44+CD62Llow effector T cells in aged
animals. However, because loss of
Noxa does not to interfere with T cell
development and homeostasis or causes730 Immunity 32, June 25, 2010 ª2010 Elsevautoimmune-related pathology (Ploner
et al., 2008), the authors considered the
possibility that it may be critical earlier
on during expansion and interclonal
selection of antigen-activated T cells.
This idea was tested by infection of wild-
type and Pmaip/ mice with influenza
virus A/PR8/34, and expansion of CD8+
effector T cells was monitored over time.
Surprisingly, although the percentage of
effector T cells was mildly elevated in
Pmaip/ animals, the percentage of
high-affinity T cells, specific for the major
influenza epitope DbNP366-374, was actu-
ally lower. As a consequence, IFN-g
production was reduced and knockout
animals recovered from infection signifi-
cantly slower than wild-type controls.
The CTL response against influenza is
usually dominated by one or two high-
affinity Vb8.3+ clones with well-defined
complementarity determining regions
(CDRs) 3, indicative for strong selection
processes during T cell expansion.
When antigen-specific T cells were sorted
at the peak of expansion on the basis of
tetramer staining and subjected to TCR
spectratyping and sequencing, Noxa-
deficient antigen-specific T cells showed
similar clonal expansion but much higher
TCR diversity. Such results suggested
that in the absence of Noxa, T cell clones
with suboptimal TCRs survive and
compete for survival factors with other,
more specific T cell clones. This situation
is reminiscent to the one found in germinalier Inc.centers in Bcl2l11/ mice where B cells
evade the selection pressure during
affinity maturation, show limited somatic
hypermutation, and produce mainly low-
affinity antibodies (Fischer et al., 2007).
For showing that the observed effects
were T cell autonomous, wild-type and
Pmaip/ T cells were transferred into
a mouse model that expresses the costi-
mulatory ligand CD70 as a transgene on
B cells, driving antigen-dependent poly-
clonal T cell expansion, but simultaneously
also lacks its receptor, CD27. In this envi-
ronment, Noxa-deficient T cells expanded
much more rapidly than their wild-type
counterparts and showed a KLRG1+
effector cell phenotype, indicative for their
descent from recently activated T cells. In
contrast, their contraction due to exhaus-
tion of naive precursor cells appeared
unaffected by loss ofPmaip1. For showing
that the effect on T cell expansion required
TCR-signaling and related affinity thresh-
olds, CD8+ T cells from OT-I and OT-I
mice lacking Pmaip1 were transferred
into isogenic recipients, subsequently
infected with low- or high-affinity pep-
tide-expressing Listeria monocytogenes
strains. Antigen-specific T cell expansion
did not differ between genotypes when it
was challenged with a high-affinity
peptide,whereasNoxa-deficientOT-I cells
performedmuchbetter than theirwild-type
OT-I counterparts when challenged with
low-affinity peptide, a phenomenon also
recapitulated in cell culture.
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PreviewsSo, how does loss of Noxa facilitate
expansion of low-affinity T cell clones
(Figure 1)? Interclonal competition has
been previously ascribed solely to qualita-
tive differences in the proliferative
response of low- versus high-affinity TCR
expressing T cell clones (Zehn et al.,
2009). Consistently, initial proliferation
rates triggered by high- versus low-affinity
peptides in OT-I T cells appeared compa-
rable and CD25 levels were found less
induced upon low-affinity peptide stimula-
tion. Most critically, this effect associated
with reduced Mcl-1 levels that were
restored by adding exogenous IL-2, in
linewith a role for commongc-chain-medi-
ated cytokine signaling in maintaining
Mcl-1 expression (Huntington et al., 2007).
Furthermore, in the absence of Noxa, the
decline of Mcl-1 appeared delayed, point-
ing toward a critical role of the Noxa-Bim-
Mcl-1 axis in apoptosis induction during
interclonal T cell competition.
Intriguingly, quantitative differences in
cell death rates between the genotypes
were not reportedby the authors, suggest-
ing that thesemay beminor, as also noted
for DNA-damage induced apoptosis in the
absence of Noxa (Ploner et al., 2008).
Therefore, biological consequences may
become evident only gradually, e.g.,
during extended in vitro culture, upon
adoptive transfer into Cd70tgCd27/
mice or in aged Pmaip/ animals. Simi-
larly, possible qualitative differences in
cell-cycle activity of Noxa-defective
T cells at later stages of antigenic chal-lenge, in which low-affinity TCR express-
ing clones reportedly stop to thrive (Zehn
et al., 2009), were not directly excluded.
Further questions arise, e.g., how critical
is the observed displacement of Bim from
Mcl-1 for death—does it activate Bax,
amember of the second class of proapop-
toticBcl-2 familyproteins, directly to kill, or
is it needed to neutralize Bcl-xL? Is Bim
indeed a critical effector during interclonal
selection, as established, e.g., in response
to cytokine-deprivation or during negative
selection (Strasser, 2005). Analysis of in-
terclonal competition in Bcl2l11/ and
Bcl2l11/Pmaip1/ mice seems war-
ranted. What are the signaling intermedi-
ates downstream of the TCR inducing
Noxa expression? It also remains unre-
solved whether Noxa acts exclusively on
Mcl-1 to promote cell death or whether
Bfl1/A1, also upregulated under these
conditions, needs to be neutralized, too.
Finally, whether Noxa is also critical for in-
terclonal selection of different T helper cell
subtypes needs to be tested.
Besides all these unresolved issues,
opening exciting and novel avenues of
research, these observations do have
implications for immuno-suppressed
patients and the elderly. Their inability to
mount effective immune responses may
not only be due to ineffective T cell activa-
tion, butpossibly alsodue to failedor com-
promised competition caused by defects
in the rheostat of involved Bcl-2 family
proteins. Hence, nonselective polyclonal
T cell activation may be a suboptimalImmunitytreatment strategy. Also, BH3 mimetics,
nonpeptidic compounds developed to kill
tumor cells, designed to selectively mimic
the action of Noxa may be a useful tool
to aid antiviral therapies or could act as a
new type of adjuvant, improving common
vaccination strategies.
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